Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Abstract:

Importance:Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objective:To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC. Design, Setting, and Participants:A single-institution, phase 2 clinical trial including 38 patients was conducted with HAI floxuridine plus systemic gemcitabine and oxaliplatin in patients with unresectable IHC at Memorial Sloan Kettering Cancer Center between May 20, 2013, and June 27, 2019. A confirmatory phase 1/2 study using the same therapy was conducted during the same time period at Washington University in St Louis. Patients with histologically confirmed, unresectable IHC were eligible. Resectable metastatic disease to regional lymph nodes and prior systemic therapy were permitted. Patients with distant metastatic disease were excluded. Interventions:Hepatic arterial infusion of floxuridine and systemic administration of gemcitabine and oxaliplatin. Main Outcomes and Measures:The primary outcome was progression-free survival (PFS) of 80% at 6 months. Results:For the phase 2 clinical trial at Memorial Sloan Kettering Cancer Center, 42 patients with unresectable IHC were included and, of these, 38 patients were treated (13 [34%] men; median [range] age at diagnosis, 64 [39-81] years). The median follow-up was 30.5 months. Twenty-two patients (58%) achieved a partial radiographic response, and 32 patients (84%) achieved disease control at 6 months. Four patients had sufficient response to undergo resection, and 1 patient had a complete pathologic response. The median PFS was 11.8 months (1-sided 90% CI, 11.1) with a 6-month PFS rate of 84.1% (90% CI, 74.8%-infinity), thereby meeting the primary end point (6-month PFS rate, 80%). The median OS was 25.0 months (95% CI, 20.6-not reached), and the 1-year OS rate was 89.5% (95% CI, 80.2%-99.8%). Patients with resectable regional lymph nodes (18 [47%]) showed no difference in OS compared with patients with node-negative disease (24-month OS: lymph node negative: 60%; 95% CI, 40%-91% vs lymph node positive: 50%; 95% CI, 30%-83%; P = .66). Four patients (11%) had grade 4 toxic effects requiring removal from the study (1 portal hypertension, 2 gastroduodenal artery aneurysms, 1 infection in the pump pocket). Subgroup analysis showed significant improvement in survival in patients with IDH1/2 mutated tumors (2-year OS, 90%; 95% CI, 73%-99%) vs wild-type (2-year OS, 33%; 95% CI, 18%-63%) (P = .01). In the Washington University in St Louis confirmatory cohort, 9 patients (90%) achieved disease control at 6 months; the most common grade 3 toxic effect was elevated results of liver function tests, and median PFS was 12.8 months (1-sided 90% CI, 6.4). Conclusions and Relevance:Hepatic arterial infusion plus systemic chemotherapy appears to be highly active and tolerable in patients with unresectable IHC; further evaluation is warranted.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Cercek A,Boerner T,Tan BR,Chou JF,Gönen M,Boucher TM,Hauser HF,Do RKG,Lowery MA,Harding JJ,Varghese AM,Reidy-Lagunes D,Saltz L,Schultz N,Kingham TP,D'Angelica MI,DeMatteo RP,Drebin JA,Allen PJ,Balachandran VP,Lim

doi

10.1001/jamaoncol.2019.3718

subject

Has Abstract

pub_date

2019-10-31 00:00:00

eissn

2374-2437

issn

2374-2445

pii

2753558

pub_type

杂志文章
  • A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

    abstract:Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.5667

    authors: Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

    更新日期:2018-05-01 00:00:00

  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

    abstract:Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.3168

    authors: Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

    更新日期:2018-04-01 00:00:00

  • Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

    abstract:IMPORTANCE:Statin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for SLCO2B1, an organic anionic transporter. We previously demonstrated that genetic variants of SLCO2B1 correlated with time to progression (TTP) durin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.0829

    authors: Harshman LC,Wang X,Nakabayashi M,Xie W,Valenca L,Werner L,Yu Y,Kantoff AM,Sweeney CJ,Mucci LA,Pomerantz M,Lee GS,Kantoff PW

    更新日期:2015-07-01 00:00:00

  • Aspirin Use and Risk of Colorectal Cancer Among Older Adults.

    abstract:Importance:Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults. Objective:To examine the association between aspirin use and the risk of incident ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.7338

    authors: Guo CG,Ma W,Drew DA,Cao Y,Nguyen LH,Joshi AD,Ng K,Ogino S,Meyerhardt JA,Song M,Leung WK,Giovannucci EL,Chan AT

    更新日期:2021-01-21 00:00:00

  • Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

    abstract:Importance:Why some triple-negative breast cancers (TNBCs) have high and others have low immune cell infiltration is unknown. Understanding how immune surveillance shapes the cancer genome could help in the selection of patients and the development of more effective immunotherapy strategies. Objective:To examine the a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.2140

    authors: Karn T,Jiang T,Hatzis C,Sänger N,El-Balat A,Rody A,Holtrich U,Becker S,Bianchini G,Pusztai L

    更新日期:2017-12-01 00:00:00

  • Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

    abstract:Importance:The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective:To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer....

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2016.1197

    authors: Powles T,Sarwar N,Stockdale A,Sarker SJ,Boleti E,Protheroe A,Jones R,Chowdhury S,Peters J,Oades G,O'Brien T,Sullivan M,Aitchison M,Beltran L,Worth D,Smith K,Michel C,Trevisan G,Harvey-Jones E,Wimalasingham A,Sahde

    更新日期:2016-10-01 00:00:00

  • Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer.

    abstract:Importance:Black individuals are underrepresented in cancer clinical trials. Objective:To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. Design, S...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3697

    authors: Senft N,Hamel LM,Manning MA,Kim S,Penner LA,Moore TF,Carducci MA,Heath EI,Lansey DG,Albrecht TL,Wojda M,Jordan A,Eggly S

    更新日期:2020-09-17 00:00:00

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.

    abstract:Importance:Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility to reduce morbidity. Objective:...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.5865

    authors: Lansu J,Bovée JVMG,Braam P,van Boven H,Flucke U,Bonenkamp JJ,Miah AB,Zaidi SH,Thway K,Bruland ØS,Baldini EH,Jebsen NL,Scholten AN,van den Ende PLA,Krol ADG,Ubbels JF,van der Hage JA,van Werkhoven E,Klomp HM,van der

    更新日期:2021-01-01 00:00:00

  • Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

    abstract:IMPORTANCE:Instituting widespread measurement of outcomes for cancer hospitals using administrative data is difficult owing to lack of cancer-specific information such as disease stage. OBJECTIVE:To evaluate the performance of hospitals that treat patients with cancer using Medicare data for outcome ascertainment and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3151

    authors: Pfister DG,Rubin DM,Elkin EB,Neill US,Duck E,Radzyner M,Bach PB

    更新日期:2015-12-01 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00

  • Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

    abstract:Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6065

    authors: Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

    更新日期:2016-05-01 00:00:00

  • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.

    abstract:Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association w...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.1771

    authors: Premenopausal Breast Cancer Collaborative Group.,Schoemaker MJ,Nichols HB,Wright LB,Brook MN,Jones ME,O'Brien KM,Adami HO,Baglietto L,Bernstein L,Bertrand KA,Boutron-Ruault MC,Braaten T,Chen Y,Connor AE,Dorronsoro M,Dossu

    更新日期:2018-11-01 00:00:00

  • Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

    abstract:Importance:Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2016.6120

    authors: Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R,Jukkola-Vuorinen A,Tanner M,Kokko R,Ahlgren J,Auvinen P,Lahdenperä O,Kosonen S,Villman K,Nyandoto P,Nilsson G,Poikonen-Saksela P,Kataja V,Junnila J,Bono P,Lindman H

    更新日期:2017-06-01 00:00:00

  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.

    abstract:Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6380

    authors: Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

    更新日期:2017-07-01 00:00:00

  • Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

    abstract:Importance:Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed in patients with subclinical disease with advanced NSCLC, and no useful clinical biomar...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5860

    authors: Toi Y,Sugawara S,Sugisaka J,Ono H,Kawashima Y,Aiba T,Kawana S,Saito R,Aso M,Tsurumi K,Suzuki K,Shimizu H,Domeki Y,Terayama K,Nakamura A,Yamanda S,Kimura Y,Honda Y

    更新日期:2019-03-01 00:00:00

  • Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

    abstract:Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HP...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6192

    authors: Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

    更新日期:2017-06-01 00:00:00

  • Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

    abstract:Importance:Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs in a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The germline genetic susceptibility to osteosarcoma outside of familial cancer syndromes remains unclear. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.0197

    authors: Mirabello L,Zhu B,Koster R,Karlins E,Dean M,Yeager M,Gianferante M,Spector LG,Morton LM,Karyadi D,Robison LL,Armstrong GT,Bhatia S,Song L,Pankratz N,Pinheiro M,Gastier-Foster JM,Gorlick R,de Toledo SRC,Petrilli AS,

    更新日期:2020-05-01 00:00:00

  • Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

    abstract:Importance:Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective:To examine the association of TTFields therapy with progression-free ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.5082

    authors: Taphoorn MJB,Dirven L,Kanner AA,Lavy-Shahaf G,Weinberg U,Taillibert S,Toms SA,Honnorat J,Chen TC,Sroubek J,David C,Idbaih A,Easaw JC,Kim CY,Bruna J,Hottinger AF,Kew Y,Roth P,Desai R,Villano JL,Kirson ED,Ram Z,

    更新日期:2018-04-01 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00

  • Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.

    abstract:IMPORTANCE:Contrary to practice guidelines, breast magnetic resonance imaging (MRI) is commonly used in the preoperative evaluation of women with breast cancer. While existing literature has found little benefit to MRI in most patients, potential downstream consequences associated with breast MRI are not well described...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3018

    authors: Arnaout A,Catley C,Booth CM,McInnes M,Graham I,Kumar V,Simos D,Van Walraven C,Clemons M

    更新日期:2015-12-01 00:00:00

  • Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.

    abstract:Importance:Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. Objective:To examine the association of chemotherapy with survival in elderly patients with mult...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2388

    authors: Tamirisa N,Lin H,Shen Y,Shaitelman SF,Sri Karuturi M,Giordano SH,Babiera G,Bedrosian I

    更新日期:2020-10-01 00:00:00

  • Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

    abstract:Importance:Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differenc...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.2993

    authors: Smeltzer MP,Faris NR,Ray MA,Osarogiagbon RU

    更新日期:2018-01-01 00:00:00

  • Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.

    abstract:Importance:Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compar...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.0997

    authors: Jalali R,Gupta T,Goda JS,Goswami S,Shah N,Dutta D,Krishna U,Deodhar J,Menon P,Kannan S,Sarin R

    更新日期:2017-10-01 00:00:00

  • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

    abstract:IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.5941

    authors: Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

    更新日期:2016-06-01 00:00:00

  • Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.

    abstract:Importance:Although adjuvant endocrine therapy confers a survival benefit among females with hormone receptor (HR)-positive breast cancer, the effectiveness of this treatment among males with HR-positive breast cancer has not been rigorously investigated. Objective:To investigate trends, patterns of use, and effective...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1114

    authors: Venigalla S,Carmona R,Guttmann DM,Jain V,Freedman GM,Clark AS,Shabason JE

    更新日期:2018-10-01 00:00:00

  • Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

    abstract:Importance:The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective:To perform a validation study of the AJCC eighth edition prognostic stage in a single-institut...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.4298

    authors: Weiss A,Chavez-MacGregor M,Lichtensztajn DY,Yi M,Tadros A,Hortobagyi GN,Giordano SH,Hunt KK,Mittendorf EA

    更新日期:2018-02-01 00:00:00

  • Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

    abstract:IMPORTANCE:The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large data...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.1184

    authors: Larkin J,Lao CD,Urba WJ,McDermott DF,Horak C,Jiang J,Wolchok JD

    更新日期:2015-07-01 00:00:00

  • Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

    abstract:IMPORTANCE:Hepatocellular carcinoma (HCC) has the second-highest cancer-related mortality rate in the world because most patients are diagnosed at an intermediate to advanced stage when surgery is not suitable. Transcatheter arterial chemoembolization (TACE) is currently considered a first-line therapy for unresectable...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2015.2189

    authors: Huo YR,Eslick GD

    更新日期:2015-09-01 00:00:00

  • Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer.

    abstract:Importance:Lay navigators in the Patient Care Connect Program support patients with cancer from diagnosis through survivorship to end of life. They empower patients to engage in their health care and navigate them through the increasingly complex health care system. Navigation programs can improve access to care, enhan...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6307

    authors: Rocque GB,Pisu M,Jackson BE,Kvale EA,Demark-Wahnefried W,Martin MY,Meneses K,Li Y,Taylor RA,Acemgil A,Williams CP,Lisovicz N,Fouad M,Kenzik KM,Partridge EE,Patient Care Connect Group.

    更新日期:2017-06-01 00:00:00